Healthcare Services

Growing geriatric population is supporting expansion in the cardiac amyloidosis market

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Cardiac Amyloidosis Market Expected To Scale Between 2026 And 2030?

The cardiac amyloidosis market has experienced significant growth in recent years. This market is expected to expand from $5.73 billion in 2025 to $6.24 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. The historical growth can be attributed to several factors including improved recognition of rare cardiac disorders, advancements in echocardiography and MRI diagnostics, an increasing number of reported amyloidosis cases, the expansion of specialist cardiology clinics, and the growing availability of supportive care options.

The cardiac amyloidosis market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $8.71 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.7%. This expansion during the forecast period can be attributed to the increasing development of disease-modifying therapies, a rising adoption of genetic testing, the expansion of specialized amyloidosis treatment centers, growing investment in rare disease research, and an increasing focus on personalized cardiac therapies. Significant trends within the forecast period include a heightened focus on early and accurate diagnosis, the rising adoption of advanced cardiac imaging techniques, a growing utilization of biomarker-based screening, the expansion of targeted therapeutic approaches, and enhanced awareness among cardiologists.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

What Key Drivers Are Fueling The Growth Of The Cardiac Amyloidosis Market?

The cardiac amyloidosis market is anticipated to experience growth driven by the expanding geriatric population. This segment of the population refers to older adults, generally aged 65 and above, who often require specific healthcare and assistance due to changes associated with aging. The rise in the geriatric population is attributed to increased life expectancy, improvements in healthcare, and declining birth rates. A larger geriatric population contributes to a higher incidence of cardiac amyloidosis, as aging is a primary risk factor for the buildup of amyloid protein in the heart. For example, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, indicating a 47% increase. Consequently, the increasing geriatric population is set to propel the cardiac amyloidosis market.

How Are Segments Identified Within The Cardiac Amyloidosis Market Segment Framework?

The cardiac amyloidosis market covered in this report is segmented –

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis

2) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy

3) By End-User: Hospitals, Clinics

Subsegments:

1) By Light Chain Amyloidosis: AL (Immunoglobulin Light Chain) Amyloidosis with Cardiac Involvement, AL Amyloidosis without Cardiac Involvement

2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

What Trends Are Influencing The Cardiac Amyloidosis Market?

Leading companies in the cardiac amyloidosis market are increasingly prioritizing technological innovations, particularly artificial intelligence (AI)-based software-only diagnostic tools, to improve early detection and patient clinical outcomes for this often underdiagnosed disease. An artificial intelligence (AI)-driven, software-exclusive medical device for identifying cardiac amyloidosis operates as a diagnostic instrument, utilizing artificial intelligence to analyze echocardiographic images and detect signs of the condition without requiring additional hardware or extensive clinical information. For example, in November 2024, Ultromics Ltd., a UK-based health technology firm, obtained FDA clearance for EchoGo Amyloidosis, an AI-powered clinical tool designed for the early detection of cardiac amyloidosis. This product represents the inaugural device in the FDA’s Total Product Lifecycle Advisory Program (TAP) to achieve marketing authorization. By leveraging artificial intelligence, EchoGo Amyloidosis scrutinizes echocardiograms to pinpoint the disease from a single clip, thereby addressing the critical need for an earlier diagnosis before the illness advances undetected.

Who Are The Companies Competing Within The Cardiac Amyloidosis Market?

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Neurimmune AG, Attralus Inc., Oncopeptides, SOM Biotech, Amylyx Pharmaceuticals, AstraZeneca plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, CSL Limited

Get The Full Cardiac Amyloidosis Market Report:

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

Where Is The Cardiac Amyloidosis Market Primarily Concentrated By Region?

North America was the largest region in the cardiac amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cardiac Amyloidosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

Browse Through More Reports Similar to the Global Cardiac Amyloidosis Market 2026, By The Business Research Company

Ventricular Fibrillation Market Report 2026

https://www.thebusinessresearchcompany.com/report/ventricular-fibrillation-global-market-report

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Cardiac Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795